Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTD regimen in relapsed/refractory Langerhans cell histiocytosis
NCT07204041Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in Langerhans cell histiocytosis (LCH), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2025; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT07204041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204041.